Biomarker ID | 800 |
PMID | 22071976 |
Year | 2011 |
Biomarker | PRKAR1A; LRRN3; PCDH17; TTN; LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1;DEFA1; DEFA1; DEFA3; DEFA1; DEFA1; CTSG; DEFA4; ELA2; |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Blood |
Subjects | Humans |
Regulation | Downregulated (0.6-0.82 fold): [PRKAR1A; LRRN3; PCDH17; TTN;] ; Upregulated (0.6 - 1.36 fold): [LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1e;DEFA1e; DEFA1e; DEFA3; DEFA1e; DEFA1e; CTSG; DEFA4; ELA2;] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(LRRN3):-TSH regulation of gene expression,Interleukin-4 regulation of apoptosis |
Experiment | Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination |
Type of Biomarker | Prognostic |
Cohort | 164 patients with metastatic castration-resistant prostate cancer were chosen. Out of which 40 were chosen as control set: (survived for >900 days (long-term survivors n =20) or died within 300 days (short-term survivors n=20). The rest are chosen as validation set. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p< 0.008 |
Method Used | qRT-PCR |
Clinical | No |
Remarks | Personalised Peptide vaccines were given to patients |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Independent Patient Cohort |
Technical Name | PRKAR1A, LRRN3, PCDH17, TTN, LAIR2, RNASE3, CEACAM6, AZU1, H4-16, PGLYRP1, CEACAM8, LCN2, MPO, CAMP, DEFA1, DEFA3, CTSG, DEFA4, ELA2 |